# Single Nucleotide Polymorphism Microarray Analysis Unveils Copy‐Number Abnormalities and Genetic Heterogeneity in Malaysian Childhood B‐Cell Precursor Acute Lymphoblastic Leukemia

**Authors:** Nor Soleha Mohd Dali, Nursaedah Abdullah Aziz, Muhamad Farid Zulkifle, Durar Aqilah Zamri, Nor Rizan Kamaluddin, Seoh‐Leng Yeoh, Betty Lee‐Sue Ho, Nazzlin Dizana Din, Azly Sumanty Ab Ghani, Wan Amal Hayati Wan Hassan, Zubaidah Zakaria, Ezalia Esa, Yuslina Mat Yusoff

PMC · DOI: 10.1002/mgg3.70182 · Molecular Genetics & Genomic Medicine · 2026-03-02

## TL;DR

This study uses SNP microarray analysis to identify genetic variations in childhood leukemia in Malaysia, revealing new insights into the disease's genetic diversity.

## Contribution

The study provides a detailed genomic profile of BCP-ALL in Malaysian children using SNP microarray and MLPA, highlighting novel copy-number abnormalities and their implications.

## Key findings

- SNP 6.0 microarray identified 191 copy-number abnormalities in 55 patients, including hyperdiploidy, hypodiploidy, and various focal abnormalities.
- Intrachromosomal amplification of chromosome 21 (iAMP21) was not observed, indicating its rarity in the Malaysian cohort.
- MLPA confirmed abnormalities in oncogenes like CDKN2A/B, EBF1, ERG, and others, supporting the combined use of SNP and MLPA for comprehensive analysis.

## Abstract

B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL) is a prevalent pediatric hematologic malignancy characterized by diverse chromosomal aberrations that significantly influence its prognosis. This study aimed to comprehensively characterize the genomic landscape of BCP‐ALL in 55 Malaysian patients with BCP‐ALL.

Single‐nucleotide polymorphism (SNP) 6.0 microarray and multiplex ligation‐dependent probe amplification were utilized to characterize and validate copy‐number abnormalities involving key oncogenes, respectively.

The SNP 6.0 microarray identified 191 copy‐number abnormalities in 55 patients, including common subtypes such as hyperdiploidy (n = 14/191, 7.3%), hypodiploidy (n = 2/191, 1.1%), and various copy‐number abnormalities such as interstitial (23.0%), terminal (17.2%), focal (37.1%), and intragenic (18.0%). Notably, intrachromosomal amplification of chromosome 21 (iAMP21) was not observed, suggesting its rarity in this cohort. Comparison with conventional cytogenetic techniques, including Trypsin‐Leishman's banding karyotyping, fluorescent in situ hybridization (FISH), and reverse transcription‐polymerase chain reaction (RT‐PCR), revealed superior resolution of the SNP 6.0 microarray in detecting submicroscopic copy‐number abnormalities. Furthermore, MLPA confirmed abnormalities in several oncogenes, including CDKN2A/B, EBF1, ERG, ETV6, IKZF1, JAK2, and PAX5.

This study demonstrates the utility of combined SNP 6.0 microarray and MLPA in providing a comprehensive and refined understanding of the genetic landscape of BCP‐ALL in the Malaysian population. This understanding may facilitate risk stratification and the development of personalized treatment strategies.

B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL) is a prevalent pediatric hematologic malignancy characterized by diverse chromosomal aberrations that significantly influence its prognosis. This study aimed to comprehensively characterize the genomic landscape of childhood BCP‐ALL in a cohort of 55 Malaysian patients.

## Linked entities

- **Genes:** cdkn2a/b (cyclin-dependent kinase inhibitor 2A/B (p15, inhibits CDK4)) [NCBI Gene 100329528], EBF1 (EBF transcription factor 1) [NCBI Gene 1879], ERG (ETS transcription factor ERG) [NCBI Gene 2078], ETV6 (ETS variant transcription factor 6) [NCBI Gene 2120], IKZF1 (IKAROS family zinc finger 1) [NCBI Gene 10320], JAK2 (Janus kinase 2) [NCBI Gene 3717], PAX5 (paired box 5) [NCBI Gene 5079]

## Full-text entities

- **Genes:** CDK4 (cyclin dependent kinase 4) [NCBI Gene 1019] {aka CMM3, MCPH31, PSK-J3}, EBF1 (EBF transcription factor 1) [NCBI Gene 1879] {aka COE1, EBF, O/E-1, OLF1}, SETD2 (SET domain containing 2, histone lysine methyltransferase) [NCBI Gene 29072] {aka HBP231, HIF-1, HIP-1, HSPC069, HYPB, KMT3A}, JAK2 (Janus kinase 2) [NCBI Gene 3717] {aka JTK10}, WWOX (WW domain containing oxidoreductase) [NCBI Gene 51741] {aka D16S432E, DEE28, EIEE28, FOR, FRA16D, HHCMA56}, CRLF2 (cytokine receptor like factor 2) [NCBI Gene 64109] {aka CRL2, CRLF2Y, TSLPR}, DPP6 (dipeptidyl peptidase like 6) [NCBI Gene 1804] {aka DPL1, DPPX, MRD33, VF2}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, NYX (nyctalopin) [NCBI Gene 60506] {aka CLRP, CSNB1, CSNB1A, CSNB4, NBM1}, PBX1 (PBX homeobox 1) [NCBI Gene 5087] {aka CAKUHED}, ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) [NCBI Gene 25] {aka ABL, BCR-ABL, CHDSKM, JTK7, bcr/abl, c-ABL}, IKZF1 (IKAROS family zinc finger 1) [NCBI Gene 10320] {aka CVID13, Hs.54452, IK1, IKAROS, LYF1, LyF-1}, IKZF3 (IKAROS family zinc finger 3) [NCBI Gene 22806] {aka AIO, AIOLOS, IMD84, ZNFN1A3}, CDKN2B (cyclin dependent kinase inhibitor 2B) [NCBI Gene 1030] {aka CDK4I, INK4B, MTS2, P15, TP15, p15INK4b}, PAX5 (paired box 5) [NCBI Gene 5079] {aka ALL3, BSAP, PAX-5}, NF1 (neurofibromin 1) [NCBI Gene 4763] {aka NFNS, VRNF, WSS}, SPTBN1 (spectrin beta, non-erythrocytic 1) [NCBI Gene 6711] {aka DDISBA, ELF, HEL102, SPTB2, betaSpII}, KMT2A (lysine methyltransferase 2A) [NCBI Gene 4297] {aka ALL-1, ALL1, CXXC7, GAS7, HRX, HTRX}, SHOX (SHOX homeobox) [NCBI Gene 6473] {aka GCFX, PHOG, SHOX1, SHOXY, SS}, CDK6 (cyclin dependent kinase 6) [NCBI Gene 1021] {aka MCPH12, PLSTIRE}, ERG (ETS transcription factor ERG) [NCBI Gene 2078] {aka LMPHM14, erg-3, p55}, RUNX1 (RUNX family transcription factor 1) [NCBI Gene 861] {aka AML1, AML1-EVI-1, AMLCR1, CBF2alpha, CBFA2, EVI-1}, FUS (FUS RNA binding protein) [NCBI Gene 2521] {aka ALS6, ETM4, FUS1, HNRNPP2, POMP75, TLS}, MACROD2 (mono-ADP ribosylhydrolase 2) [NCBI Gene 140733] {aka C20orf133, C2orf133}, KMT2D (lysine methyltransferase 2D) [NCBI Gene 8085] {aka AAD10, ALR, BCAHH, CAGL114, KABUK1, KMS}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, NSF (N-ethylmaleimide sensitive factor, vesicle fusing ATPase) [NCBI Gene 4905] {aka DEE96, SEC18, SKD2}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, TCF3 (transcription factor 3) [NCBI Gene 6929] {aka AGM8, AGM8A, AGM8B, E2A, E47, ITF1}, HNF4A (hepatocyte nuclear factor 4 alpha) [NCBI Gene 3172] {aka FRTS4, HNF4, HNF4a7, HNF4a8, HNF4a9, HNF4alpha}, CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, BTG1 (BTG anti-proliferation factor 1) [NCBI Gene 694] {aka APRO2}, HBB (hemoglobin subunit beta) [NCBI Gene 3043] {aka CD113t-C, ECYT6, beta-globin}, PRKCD (protein kinase C delta) [NCBI Gene 5580] {aka ALPS3, CVID9, MAY1, PKCD, nPKC-delta}, ETV6 (ETS variant transcription factor 6) [NCBI Gene 2120] {aka TEL, TEL/ABL, THC5}, NRAS (NRAS proto-oncogene, GTPase) [NCBI Gene 4893] {aka ALPS4, CMNS, N-ras, NCMS, NRAS1, NS6}, TKT (transketolase) [NCBI Gene 7086] {aka HEL-S-48, HEL107, SDDHD, TK, TKT1}, BCR (BCR activator of RhoGEF and GTPase) [NCBI Gene 613] {aka ALL, BCR1, CML, D22S11, D22S662, PHL}, EPOR (erythropoietin receptor) [NCBI Gene 2057] {aka EPO-R}, NPHP4 (nephrocystin 4) [NCBI Gene 261734] {aka POC10, SLSN4}, DUX4 (double homeobox 4) [NCBI Gene 100288687] {aka DUX4L}, PWAR1 (Prader Willi/Angelman region RNA 1) [NCBI Gene 145624] {aka D15S227E, PAR-1, PAR1}, RB1 (RB transcriptional corepressor 1) [NCBI Gene 5925] {aka OSRC, PPP1R130, RB, p105-Rb, p110-RB1, pRb}, KANSL1 (KAT8 regulatory NSL complex subunit 1) [NCBI Gene 284058] {aka C17DELq21.31, CENP-36, DEL17Q21.31, KDVS, KIAA1267, MSL1v1}, KRT2 (keratin 2) [NCBI Gene 3849] {aka CK-2e, K2e, KRT2A, KRT2E, KRTE}, OPN1SW (opsin 1, short wave sensitive) [NCBI Gene 611] {aka BCP, BOP, CBT}
- **Diseases:** aneuploidy (MESH:D000782), Copy-Number (MESH:D007674), genomic abnormalities (MESH:D042822), ALL (MESH:D054198), leukemia (MESH:D007938), genetic abnormalities (MESH:D030342), acute myeloid leukemia (MESH:D015470), hematologic malignancy (MESH:D019337), beta-thalassemia (MESH:D017086), B-Cell Precursor Acute Lymphoblastic Leukemia (MESH:D015452), pediatric (MESH:D063766), Cancer (MESH:D009369), chromosomal abnormalities (MESH:D002869), Down Syndrome (MESH:D004314)
- **Chemicals:** BFM95 (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** P358/16 — Homo sapiens (Human), Minimally invasive lung adenocarcinoma, Cancer cell line (CVCL_1559), P32/16 — Homo sapiens (Human), EBV-related Burkitt lymphoma, Cancer cell line (CVCL_3119), 16 — Homo sapiens (Human), Telomerase immortalized cell line (CVCL_B6EN)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12953716/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12953716/full.md

## References

46 references — full list in the complete paper: https://tomesphere.com/paper/PMC12953716/full.md

---
Source: https://tomesphere.com/paper/PMC12953716